.

Citation: *Egypt.Acad.J.Biolog.Sci. (C.Physiology and Molecular biology) Vol. 17(1) pp41-67 (2025)*
DOI: 10.21608/EAJBSC.2025.411912

Egypt. Acad. J. Biolog. Sci., 17(1):41-67 (2025)

Egyptian Academic Journal of Biological Sciences
C. Physiology & Molecular Biology
ISSN 2090-0767
www.eajbsc.journals.ekb.eg



Harnessing Microbial Ecosystems in Health and Disease: Innovations in Medical Microbiology for Advancing Precision Medicine and Therapeutic Strategies

Shazia S. Mir
Laboratory Medicine Department, Faculty of Applied Medical Sciences, Al-Baha University, Al-Baha - 65779, Saudi Arabia
***E-mail:** smir@bu.edu.sa

REVIEW INFO
Review History
Received:5/1/2025
Accepted:16/2/2025
Available:20/2/2025

Keywords:
Microbial ecosystems; Human microbiome; Precision medicine; Medical microbiology; Therapeutic innovations; Metagenomics; Multi-omics integration.

ABSTRACT

Advances in medical microbiology continue to uncover novel insights into microbial ecosystems and their intricate interactions with human health and disease. This review aims to elucidate how innovative investigative tools, including high-throughput sequencing, metagenomics, and advanced bioinformatics, are transforming the study of the human microbiome. By investigating complex microbial interactions, this review identifies key players in maintaining homeostasis and contributing to disease pathogenesis. The overarching objective is to explore how these advancements drive the emergence of precision medicine, enabling interventions tailored to an individual's unique microbial composition. Integration of multi-omics data, such as genomics, metagenomics, and metabolomics, is highlighted as a cornerstone for developing personalized therapeutic options. Characterizing microbial signature profiles associated with health conditions empowers clinicians to prescribe targeted treatments, optimizing outcomes and minimizing adverse effects. Moreover, an understanding of microbial dynamics catalyses the development of novel therapeutic strategies, including new antimicrobial agents, next-generation probiotics, and microbiome modulation techniques. These innovations underline the transformative role of microbial ecosystems in advancing precision medicine and therapeutic innovations. By leveraging microbial insights, this interdisciplinary research opens new pathways for tailored health strategies and more effective disease management.

INTRODUCTION

The human microbiome, comprising trillions of microorganisms residing in and on the body, plays a fundamental role in various physiological processes (Turnbaugh *et al.*, 2007). The symbiotic relationship between humans and the microbial communities inhabiting their bodies is a dynamic and complex interplay that significantly influences both health and disease states. The last decade has witnessed a revolutionary shift in our understanding of the human microbiome, fuelled by advancements in high-throughput sequencing, metagenomics, and bioinformatics (Consortium, 2012). This paradigm shift has paved the way for exploring innovative applications in medical microbiology, with a particular emphasis on precision medicine and therapeutic advancements. Microorganisms, including bacteria, viruses, fungi, and archaea, coexist within the human body in a delicate equilibrium, collectively forming the microbiome (Lozupone and Knight, 2007). These microbial communities play crucial roles in nutrient metabolism, immune system development, and protection against pathogens, creating a delicate balance essential for maintaining health (Peixoto *et al.*, 2022; Rowland *et al.*, 2018; Yoo *et al.*, 2020).

To further understand these microbial ecosystems and their influence on health, researchers have developed advanced tools and technologies that enable a deeper exploration of the microbiome's composition and functionality.

The advent of cutting-edge technologies has enabled researchers to decipher the composition and functionality of the microbiome with unprecedented precision. High-throughput sequencing techniques provide a comprehensive view of microbial diversity, allowing scientists to identify key players in health maintenance and disease onset. Single-cell sequencing technologies are now enabling researchers to characterize individual microbial cells, revealing finer details about functional heterogeneity within microbial communities (Hare *et al.,* 2021; Wu *et al.,* 2024). Similarly, synthetic biology is paving the way for engineering microbiota to target specific health conditions, such as metabolic disorders or immune dysregulation (Bober *et al.,* 2018; Nazir *et al.,* 2024). Emerging approaches, including artificial intelligence (AI) and machine learning, are being leveraged to analyze complex microbiome data, enabling predictive modelling for disease outcomes and personalized therapeutic recommendations (D'Urso and Broccolo, 2024). These technological advancements have provided new insights into the microbiome's role in various diseases, revealing its systemic influence on human health. Recent research has also highlighted the gut-brain axis as a critical pathway linking the microbiome to neurological health. Alterations in gut microbiota have been associated with neurodegenerative diseases such as Alzheimer's and Parkinson's, suggesting their systemic influence extends beyond traditional physiological processes (Loh *et al.,* 2024; Westfall *et al.,* 2017). The gut microbiota's influence extends to cardiovascular health, with microbial dysbiosis contributing to serious conditions such as atherosclerosis (Tang *et al.,* 2019). Furthermore, microbiota modulation is increasingly recognized as a potential strategy in cancer prevention and treatment, as exemplified by its role in colorectal cancer pathogenesis (Fong *et al.,* 2020). These insights emphasize the critical role of microbial communities in both health maintenance and disease progression.

Additionally, the complex interplay between microbial communities and host physiology requires further exploration to identify precise therapeutic targets and strategies. A comprehensive synthesis of current knowledge that bridges technological innovations with clinical applications is essential for advancing precision medicine and developing effective, individualized interventions. Building on these discoveries, precision medicine has emerged as a transformative approach, leveraging microbial data to tailor healthcare interventions for individual patients. By unravelling the specific microbial signatures associated with health and various disease states, clinicians can tailor interventions to optimize therapeutic outcomes. The development of targeted antimicrobial agents, the exploration of probiotics, and the modulation of the microbiome present innovative avenues for disease management (Chou *et al.,* 2022). These therapeutic advancements aim to restore and maintain microbial balance, creating a patient-centred approach to treatment. Despite these promising developments, challenges such as ethical concerns and standardization barriers must be addressed to fully realize the potential of microbiome research in clinical applications.

While these advancements have significantly expanded our understanding of microbial ecosystems, critical gaps remain. Specifically, translating microbiome research into actionable clinical applications has been hindered by challenges in integrating multi-omics data, addressing inter-individual variability, and overcoming the lack of standardized methodologies for data analysis. Despite significant advancements, several challenges persist. Ethical concerns related to

patient privacy in microbiome data and equitable access to precision medicine need careful consideration. Standardizing methodologies for microbiome analysis remains critical to ensuring reproducibility across studies (Ahmed and Hens, 2022; Brothers and Rothstein, 2015). Looking ahead, integrating microbiome data with clinical systems, such as electronic health records, and leveraging AI-driven analytics will enhance precision in clinical decision-making. Continued research into microbiome-host interactions and the development of targeted interventions are vital for unlocking the full potential of microbial ecosystems in human health. The primary objective of this review is to explore the pivotal role of microbial ecosystems in shaping health and disease outcomes. By synthesizing advancements in medical microbiology, this review demonstrates how emerging technologies enable the study of microbial ecosystems and drive innovations in precision medicine and therapeutic strategies. It highlights the integration of cutting-edge methodologies to tailor healthcare interventions, contributing to more effective and individualized treatments.

MATERIALS AND METHODS

The exploration of microbial dynamics in health and disease, with a focus on innovations in medical microbiology for precision medicine and therapeutic advancements, requires a robust set of research methods. The integration of cutting-edge technologies and interdisciplinary approaches is essential to unravel the complexity of microbial interactions (Fig. 1). Advances in high-throughput sequencing, multi-omics integration, and bioinformatics have revolutionized microbiome research, allowing for unprecedented precision in characterizing microbial communities and their functional roles. Fig. 1 highlights the distinct compositions of microbiota across different body regions, emphasizing the analytical methods tailored to study their unique characteristics. For instance, next-generation sequencing (NGS) technologies facilitate comprehensive profiling of microbial genomes, while metagenomics uncovers novel microorganisms and functional pathways relevant to disease processes. These approaches not only enhance our understanding of microbial ecosystems but also bridge the gap between fundamental research and clinical applications.



Fig. 1: Microbiota composition in different regions.

Below are key research methods that contribute to advancing our understanding the microbiota composition in our body:

High-Throughput Sequencing:

Utilizing next-generation sequencing technologies allows for the rapid and comprehensive analysis of microbial genomes and metagenomes. Recent advances in third-generation sequencing technologies, such as PacBio and Oxford Nanopore, have further enhanced the ability to resolve complex microbial genomes, enabling higher accuracy in microbiome characterization (Han et al., 2024; Satam et al., 2023). This enables the profiling of microbial communities, identifying specific taxa and their functional potential (Alsayed et al., 2023; Reuter et al., 2015; Xu and Yang, 2020). NGS platforms, such as Illumina and PacBio, are widely used for their ability to provide high-resolution insights into microbial diversity and functional capabilities.

Metagenomics:

Examining the genetic material recovered directly from environmental samples, metagenomics provides insights into the collective genomic content of microbial communities. This allows the identification of novel microorganisms, functional genes, and potential pathways relevant to health and disease (Pavlopoulos et al., 2023). The integration of long-read sequencing into metagenomics workflows has significantly improved the discovery of novel microbial taxa and functional pathways, addressing challenges posed by short-read limitations (Han et al., 2024; Kim et al., 2024). Metagenomics is particularly impactful in uncovering the "dark matter" of microbial ecosystems, enhancing our understanding of unculturable microbes.

Multi-Omics Integration:

Integrating genomics, metagenomics, transcriptomics, proteomics, and metabolomics data provides a holistic view of microbial dynamics. Advanced computational tools, including machine learning algorithms and network-based models, have revolutionized multi-omics research, enabled the discovery of actionable biomarkers and facilitated precision medicine applications (Vitorino, 2024). Enables the identification of microbial signatures associated with health conditions and facilitates the development of precision medicine strategies (Subramanian et al., 2020). Multi-omics integration bridges gaps between data layers, offering comprehensive insights into host-microbe interactions and their role in disease processes.

Bioinformatics and Computational Analysis:

Leveraging advanced bioinformatics tools is crucial for processing and interpreting large-scale omics data. The adoption of graph-based algorithms and platforms like HUMAnN3 has greatly improved the functional profiling of microbial communities, facilitating the identification of microbial pathways and host-microbiome interactions (Beghini et al., 2021). This facilitates the identification of microbial biomarkers, predictive models, and the discovery of potential therapeutic targets (Pereira et al., 2020) (Fig. 2). The flowchart outlines the stages of bioinformatics analysis, from raw data acquisition to functional interpretation, demonstrating how computational tools streamline the understanding of microbial ecosystems.

Microbiome Culturing and Isolation:

Traditional microbiological techniques, such as culturing and isolating microorganisms, remain important for characterizing individual strains and their functional roles. Allows for in-depth study of microbial physiology and behaviour under controlled conditions (Wan et al., 2023). Advances in culturomics have expanded the ability to isolate previously unculturable organisms, bridging gaps in functional studies.

Functional Genomics:

Investigating the functional roles of microbial genes through techniques such as

CRISPR-Cas9, RNA interference, and gene expression analysis. Provides insights into how specific microbial functions contribute to health or disease states (Konstantinov *et al.*, 2013). Functional genomics is pivotal in understanding host-microbe interactions and identifying novel therapeutic targets.



Fig. 2: Flow chart of bioinformatics analysis.

***In Vivo* and *In Vitro* Models:**

Utilizing animal / human models or cell culture systems to study host-microbe interactions. Recent developments in organoid technology, such as gut organoids, have enhanced the physiological relevance of in vitro systems, providing more accurate insights into host-microbe interactions (Poletti *et al.*, 2021; Rauth et al., 2021). This facilitates the exploration of microbial dynamics in a controlled environment, allowing for the testing of therapeutic interventions (Biagini *et al.*, 2020; Van den Abbeele *et al.*, 2023; Venema and Van den Abbeele, 2013) (Fig. 3). Figure 3, illustrates the division between *in vitro* and *in vivo* datasets, highlighting the complementary roles of these models in elucidating microbial dynamics and testing interventions.

Antimicrobial Susceptibility Testing:

Assessing the sensitivity of microbial strains to various antimicrobial agents. Essential for the development of targeted therapies and understanding microbial resistance patterns (Hromada and Venturelli, 2023). This approach contributes to precision medicine by guiding the selection of effective antimicrobial agents.



Fig. 3: Charts showing the division of *in vitro* and *in vivo* datasets.

Clinical Sampling and Epidemiological Studies:

Collecting and analyzing clinical samples from human populations to identify correlations between microbial profiles and health outcomes. These studies are indispensable for understanding microbial dynamics in real-world scenarios (Ma *et al.*, 2023). These studies further elucidate the links between microbial shifts and disease prevalence across diverse populations.

Therapeutic Trials and Intervention Studies:

The clinical trials are used to assess the efficacy of novel therapeutic interventions, including probiotics, microbiome modulation, and precision medicine approaches. Recent trials have demonstrated the efficacy of personalized probiotics and engineered microbiota in treating metabolic and immune-related disorders, underscoring their potential for targeted therapies (Abouelela and Helmy, 2024; Tiwari *et al.*, 2024). These studies bridge research findings and clinical applications, advancing the field of personalized medicine (Lagkouvardos *et al.*, 2023). By employing these diverse research methods, investigators can unravel the complexities of microbial dynamics, paving the way for innovative discoveries in medical microbiology that hold the potential to revolutionize precision medicine and therapeutic strategies for improved patient outcomes (Russell *et al.*, 2023).

RESULTS AND DISCUSSION

The results and discussion section will provide an integrated analysis of how microbial dynamics shape health and disease outcomes, leveraging cutting-edge methodologies and their applications in medical microbiology. This section examines the systemic functions of microbiota, the transformational capabilities of technology innovations, and the ramifications for precision medicine and treatment approaches. A thorough analysis reveals the dual role of microbial communities as both guardians and antagonists of health, providing insights into their manipulation for disease prevention and therapy. This discourse underscores the need for collaborative strategies to convert microbiome research into efficacious therapeutic applications.

Innovations in Medical Microbiology:

Medical microbiology is experiencing a fast evolution, propelled by technology innovations that are redefining

our comprehension of the microbiome and its effects on human health. These breakthroughs have transformed microbiome research and facilitated new diagnostic and treatment methods. Significant developments encompass:

Next-Generation Sequencing (NGS):

Next-generation sequencing (NGS) has become a cornerstone of microbiome research, offering high-throughput and comprehensive characterization of microbial populations. Unlike conventional culture methods, NGS enables the identification and quantification of both culturable and non-culturable bacteria, thereby uncovering the full spectrum of microbial diversity. This capability is particularly vital in cancer research, where NGS elucidates the complex relationships between gut microbiota, carcinogenesis, tumor progression, and therapeutic outcomes. NGS facilitates the exploration of microbial metabolic pathways and gene functions, providing insights into the microbiome's potential roles in cancer progression. Functional analysis of gut microbiota has identified microbial genes involved in critical processes such as inflammation, DNA repair, and metabolism pathways closely associated with cancer development. Comprehensive investigations facilitated by NGS have clarified how the microbiota can either promote or suppress cancer, offering insights crucial for developing microbiome-targeted therapies. The ability of NGS to handle vast, intricate datasets is a significant advantage, but it requires advanced bioinformatics tools for effective processing and interpretation. These tools enable researchers to accurately identify key microbial entities and their functional roles, advancing our understanding of microbial contributions to cancer (Li, C. *et al.,* 2024; Satam *et al.,* 2023). Additionally, NGS's high sensitivity enables the detection of rare microbial species that traditional methods might overlook. Despite their low abundance, these rare taxa can play significant roles in cancer-related processes, either through direct host-microbe interactions or by influencing the overall microbial ecosystem. By uncovering these hidden microbial players, NGS supports the development of innovative diagnostic tools and therapeutic approaches, enhancing precision in cancer care.

The application of machine learning (ML) further enhances the utility of NGS in microbiome research. ML models excel in identifying subtle patterns that traditional analyses might miss, particularly in cancer studies. While most prior research has focused on distinct microbial signatures for individual tumours, ML provides the tools to explore shared microbial profiles across various cancer types. These models have been applied primarily in colorectal cancer research but are now expanding to other cancers, potentially uncovering biomarkers for treatment response and early diagnosis (Zhang *et al.,* 2019). ML leverages diverse sample types including blood, tissue biopsies, mucosal swabs, and faeces, each providing unique insights into host-microbe interactions. However, contamination remains a significant challenge, as external DNA or cross-contamination can distort results. Functional data is increasingly recognized as a vital complement to traditional taxonomic profiles in ML applications, improving prediction accuracy and enabling a deeper understanding of microbiota-cancer connections. High-throughput functional profiling enabled by NGS opens new avenues for integrating multiple data types and enhancing cancer detection. Addressing challenges such as data sparsity, variability, and high zero-value frequencies in microbiome datasets is essential for advancing ML's capabilities in this field.

NGS platforms have diversified, offering a range of technologies tailored to specific research needs. Short-read platforms like Illumina and Ion Torrent provide high accuracy and cost-effectiveness, making them ideal for microbial diversity and metagenomic studies. Illumina’s sequencing-by-synthesis method generates highly accurate short reads, while Ion Torrent’s ion-sensitive detection system offers a faster

sequencing process, albeit with slightly lower accuracy in some applications (Zhang *et al.*, 2019). In contrast, long-read platforms such as PacBio and Oxford Nanopore address limitations in genome assembly and structural resolution. PacBio's single-molecule real-time (SMRT) sequencing produces long, highly accurate reads, enabling complete genome reconstruction and epigenetic analysis. Oxford Nanopore offers real-time sequencing with portable devices, excelling in environmental sampling and rapid microbial diagnostics. Emerging technologies like Element Biosciences and Singular Genomics are transforming the sequencing landscape by improving accuracy, speed, and cost efficiency. Element Biosciences focuses on reducing sequencing costs without compromising data quality, while Singular Genomics provides versatile systems for microbiome and personalized medicine applications (Hemmati *et al.,* 2024). The integration of diverse sequencing technologies offers a synergistic approach to overcoming individual platform limitations. For instance, combining PacBio or Oxford Nanopore's long-read capabilities with Illumina's high accuracy allows for comprehensive microbial genome reconstruction and ecosystem analysis (Cook *et al.,* 2024; Xia *et al.,* 2023). These multi-technology approaches not only enhance data clarity but also enable the identification of complex host-microbiome interactions. This integration accelerates discoveries in antibiotic resistance profiling, precise microbial composition analysis, and personalized treatment plans. By adopting cutting-edge platforms, researchers can broaden access to advanced sequencing methods and deepen their understanding of the microbiome's impact on health and disease (Li, C. *et al.,* 2024; Zhang *et al.,* 2019).

Advances in the Metagenomics and Cancer Research:

Meta-omics technologies are increasingly employed to investigate the gut microbiome's role in cancer, offering critical insights into its genetic composition and metabolic functions (Hemmati *et al.,* 2024; Mathuria *et al.,* 2024). Methods such as shotgun metagenomics and metabolomics have identified specific bacterial species linked to colorectal cancer, underscoring the microbiome's significant role in oncogenesis. The human intestine represents a complex ecosystem of host cells, microbial communities, and molecules (Quince *et al.,* 2017). To capture the functional dynamics within this ecosystem, meta-transcriptomics and meta-proteomics are used to measure RNA transcripts and proteins, providing detailed insights into the microbiome's active processes and its interactions with the host. Shotgun metagenomics is a particularly powerful tool, analyzing all DNA fragments in a sample to yield precise information on microbial species abundance, taxonomic composition, and functional potential (Aizpurua *et al.,* 2024). This approach enables the reconstruction of complete microbial genomes, enhancing taxonomic and functional understanding. However, its focus on genetic potential does not always reflect actual microbial activity (Quince *et al.,* 2017). Integrating metagenomics with meta-transcriptomics addresses this limitation by coupling genetic data with gene expression profiles, providing a more nuanced view of the gut microbiome's role in health and disease (Kumar and Yadav, 2024). This synergy between technologies delivers a valuable, multi-dimensional understanding of microbiome functionality, which is especially relevant for exploring its involvement in cancer biology.

Metagenomics also sheds light on host-microbiome interactions that may increase susceptibility to cancer. It reveals differences in microbial diversity and identifies species with oncogenic or protective roles. For instance, changes in metabolites such as bile acids and short-chain fatty acids (SCFAs) have been linked to cancer risk through their influence on cellular proliferation and inflammation pathways (Zeng *et al.,* 2019). Additionally, meta-omics approaches can detect variations in microbial composition and metabolic profiles before

clinical symptoms appear, aiding in early cancer diagnosis (Visekruna and Luu, 2021). By integrating various meta-omics technologies, a systems biology perspective is achieved, allowing for precise cancer risk predictions based on microbial-host interactions, environmental factors, and metabolic alterations (Hemmati *et al.,* 2024). These comprehensive insights pave the way for early interventions and personalized preventive strategies tailored to an individual's unique microbial and metabolic profile. Meta-omics technologies are thus transforming cancer research, opening new doors for individualized treatments and enhancing our understanding of the microbiome's role in oncogenesis.

Gnotobiotic Animal Models:

Gnotobiotic animal models, especially germ-free (GF) mice, are essential instruments in biomedical research for examining host-microbiota interactions in regulated environments (Wostmann, 2020). These models are either entirely free of microorganisms or selectively populated with known microbial communities, enabling researchers to examine the functions of individual bacteria in health and illness. Gnotobiotic models have been instrumental in elucidating the influence of microbiota on immune system maturation. Studies using GF mice have demonstrated that the absence of gut microbiota leads to underdeveloped immune structures and altered immune responses (Tlaskalová-Hogenová *et al.,* 2011). Introducing specific microbial species into these models has shown how particular bacteria contribute to the development of immune functions (Kubelkova *et al.,* 2016). These models have been used to explore the impact of microbiota on host metabolism. For instance, research involving GF mice colonized with specific bacterial strains has provided insights into how gut microbiota influence nutrient absorption, energy balance, and fat storage, shedding light on conditions like obesity and diabetes (Basic and Bleich, 2019). Gnotobiotic models have facilitated the study of the gut-brain axis. Experiments with GF mice have revealed that the absence of microbiota can affect brain development and behavior, indicating a significant role of gut bacteria in neurological health (Morais *et al.,* 2021; Sherwin *et al.,* 2018). Gnotobiotic animals are employed to study pathogen-host interactions without the confounding presence of other microorganisms. This approach has been crucial in understanding the pathogenicity of various microbes and the host's immune responses (Lange *et al.,* 2023). Recent studies have expanded and provided enhanced vision on the use of gnotobiotic models in real time analysis along with some clinical trials, which are summarised as follows:

- **Microbiota and Exercise Physiology:** Research has utilized gnotobiotic models to investigate how specific gut microbes influence exercise performance and adaptation (Huang *et al.,* 2019). These studies aim to identify potential probiotic candidates that could enhance physical performance.
- **Gnotobiotic Zebrafish:** Beyond rodents, gnotobiotic zebrafish have been developed to study host-microbiota interactions in a simpler vertebrate model, providing insights into microbial influences on development and disease (Burns and Guillemin, 2017).
- **Gnotobiotic piglets:** Gnotobiotic piglets are valuable for studying human gastrointestinal diseases due to their physiological similarities to humans. They have been used to investigate the role of gut microbiota in immune system development and responses to infections. For instance, studies utilizing gnotobiotic piglets have provided insights into how microbial colonization influences the maturation of the immune system and the development of gut-associated lymphoid tissues (Kubelkova *et al.,* 2016; Vlasova *et al.,* 2018).
- **Gnotobiotic Drosophila (Fruit Flies):** Drosophila melanogaster serves as a model for studying microbial interactions due to its simple gut microbiota and well-characterized genetics. Gnotobiotic Drosophila models have been used to

investigate how specific microbes influence host metabolism, immunity, and lifespan. These studies provide insights into fundamental aspects of host-microbe interactions that can be relevant to higher organisms (Grenier and Leulier, 2020).

- **Gnotobiotic Rats**: Like mice, gnotobiotic rats are used to study the effects of microbiota on physiology and disease. They offer advantages in certain research areas, such as cardiovascular studies, due to differences in physiology compared to mice. Gnotobiotic rats have been utilized to explore the role of gut microbiota in hypertension and other metabolic disorders (Basic and Bleich, 2019).
- **Gnotobiotic *C. elegans***: The nematode *Caenorhabditis elegans* is another model organism used in gnotobiotic research. Its simple anatomy and transparent body make it suitable for studying microbial colonization and its effects on host biology. Gnotobiotic *C. elegans* models have been employed to understand microbial influences on development, aging, and behavior (Kumar *et al.*, 2020; National Academies of Sciences and Medicine, 2018).
- **Clinical Trials Involving Gnotobiotic Models:** While gnotobiotic models are primarily used in preclinical research, insights gained from these studies inform clinical trials. For example, understanding how specific gut microbes influence drug metabolism in gnotobiotic animals can lead to more targeted probiotic therapies in humans. Additionally, findings from gnotobiotic studies have paved the way for clinical trials investigating faecal microbiota transplantation as a treatment for conditions like *Clostridioides difficile* infection and inflammatory bowel disease (Tkach *et al.*, 2023).

In summary, a diverse array of gnotobiotic models, including piglets, zebrafish, rats, Drosophila, and *C. elegans*, complement traditional GF mouse studies. These models provide unique insights into host-microbiota interactions across different physiological contexts, enhancing our understanding of microbial contributions to health and disease. While gnotobiotic models offer precise control over microbial exposure, they come with challenges:

- **Technical Complexity**: Maintaining germ-free conditions requires specialized facilities and rigorous protocols to prevent contamination (Kennedy *et al.*, 2018).
- **Physiological Differences**: GF animals may exhibit anatomical and physiological differences from conventionally raised counterparts, such as enlarged cecum and altered immune responses, which must be considered when interpreting results (Cowieson, 2022; Kim, 2025).

Human Microbiomes:

The human microbiome encompasses diverse microbial communities residing in various organs, each playing a crucial role in maintaining health and influencing disease states. This section of the review will provide an overview of the microbiomes associated with the oral, respiratory tract, gut, skin, and urogenital (Vagina) organs (Fig. 1).

- **Oral Microbiome:** The oral microbiome is a diverse community of microorganisms, including bacteria, fungi, viruses, and archaea, residing in the mouth. This microbiome plays a critical role in maintaining oral and systemic health by forming a protective barrier against pathogens, contributing to digestion, and influencing the immune system (Sedghi *et al.*, 2021). However, imbalances in the oral microbiome, or dysbiosis, can lead to both localized and systemic diseases.
- **Respiratory tract microbiome:** The respiratory tract harbours a unique microbiome that contributes to immune defence and respiratory health. Disruptions in this microbiome have been linked to conditions such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections (Li, R. *et al.*, 2024; Pathak *et al.*, 2025). Recent studies have explored the interactions between the respiratory and gut microbiomes, suggesting a bidirectional relationship that influences systemic immunity (Invernizzi *et al.*, 2020; Zhao *et al.*, 2025).

- **Gut Microbiome:** The gut microbiome is the most extensively studied, comprising trillions of microorganisms that aid in digestion, nutrient absorption, and immune modulation (Shang *et al.,* 2024). Alterations in gut microbiota composition, known as dysbiosis, have been associated with various diseases, including inflammatory bowel disease (IBD), obesity, and metabolic disorders (Carding *et al.,* 2015). Emerging research highlights the gut's interaction with other organ systems, supporting the concept that many diseases may have origins linked to gut health (Hsu *et al.,* 2024; Morais *et al.,* 2021; Van Hul *et al.,* 2024).
- **Skin Microbiome:** The skin microbiome consists of bacteria, fungi, and viruses that protect against pathogens and contribute to skin health (Dréno *et al.,* 2016; Lee and Kim, 2022). Disruptions in this microbiome can lead to conditions such as acne, eczema, and psoriasis (Mazur *et al.,* 2021). Recent studies have focused on the stability and variability of the skin microbiome across different body sites, emphasizing its role in both local and systemic health (Wang *et al.,* 2017).
- **Vaginal Microbiome**: The vaginal microbiome is predominantly composed of Lactobacillus species, which maintain an acidic environment to protect against infections. Alterations in this microbiome are linked to conditions like bacterial vaginosis and increased susceptibility to sexually transmitted infections (Sadeghpour Heravi, 2024). Recent research has examined the dynamic changes in the vaginal microbiota throughout a woman's lifespan and its impact on reproductive health (Das *et al.,* 2023; Grobeisen-Duque *et al.,* 2023; Lehtoranta *et al.,* 2022).
- **Gut-Vagina Microbiome Crosstalk:** Emerging evidence suggests a connection between the gut and vaginal microbiomes, where dysbiosis in one may influence the other (Saraf et al., 2021). This interplay has implications for conditions such as endometriosis and other reproductive health issues (Meštrović et al., 2020). Understanding this crosstalk could lead to novel therapeutic strategies targeting multiple microbiome sites simultaneously.

Influence of Gut Microbiome on Systemic Health:

The gut microbiome plays a pivotal role in systemic health, influencing not only local gastrointestinal function but also distant organs and systems through complex interactions. Emerging research highlights that dysbiosis - an imbalance in the gut microbial community is associated with several systemic diseases, including neurological, cardiovascular, and metabolic disorders.

Neurological Health and the Gut-Brain Axis:

The gut-brain axis represents a bidirectional communication pathway between the gut microbiota and the central nervous system (Ohara and Hsiao, 2025). Alterations in gut microbiota composition have been implicated in neurodegenerative diseases such as Alzheimer's and Parkinson's disease. For instance, reduced levels of short-chain fatty acids (SCFAs), which are microbial metabolites, have been linked to neuroinflammation and cognitive decline in Alzheimer's disease (Liu *et al.,* 2025; Trisal *et al.,* 2025). Similarly, studies suggest that certain gut bacterial strains exacerbate α-synuclein aggregation, a hallmark of Parkinson's disease.

Cardiovascular Health:

The gut microbiota significantly influences cardiovascular health through metabolite production, such as trimethylamine-N-oxide (TMAO). TMAO, derived from dietary choline and L-carnitine by gut bacteria, has been shown to promote atherosclerosis, increasing the risk of heart disease (Tang *et al.,* 2017). Conversely, SCFAs, produced by the fermentation of dietary fiber, have anti-inflammatory properties that protect against hypertension and cardiovascular complications (Nogal *et al.,* 2021).

Metabolic Disorders:

Dysbiosis is a recognized contributor to metabolic disorders, including obesity and

type 2 diabetes. An imbalance in gut microbial diversity has been shown to impair glucose metabolism and insulin sensitivity. An overgrowth of certain Firmicutes species relative to Bacteroidetes is associated with increased energy harvest from the diet, contributing to weight gain (Profir *et al.,* 2025). Pro-inflammatory metabolites from dysbiotic microbiota also exacerbate insulin resistance, linking gut health to metabolic syndrome (Marwaha *et al.,* 2025).

Cancer Development:

The gut microbiota is increasingly recognized as a modulator of carcinogenesis (Mahmoudian *et al.,* 2025). In colorectal cancer, for example, *Fusobacterium nucleatum* promotes tumor growth by activating inflammatory and immune pathways (Chen *et al.,* 2025). Conversely, a diverse and balanced gut microbiota appears protective, reducing pro-carcinogenic activity through enhanced production of anti-inflammatory metabolites (Hamamah *et al.,* 2024).

Immune System Modulation:

The gut microbiome is intricately linked to immune system development and function. Dysbiosis has been implicated in autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease (IBD). Specific gut bacteria influence T-cell differentiation, leading to either pro-inflammatory or anti-inflammatory states that directly impact systemic immune responses (Cristofori *et al.,* 2021).

Microbiome-Based Therapeutics In Humans:

Microbiome-based therapeutics have emerged as a promising frontier in medicine, aiming to modulate the human microbiome to treat various diseases. Recent advancements and clinical trials have highlighted several key developments in this field:

- **Faecal Microbiota Transplantation (FMT)**: FMT is a procedure that directly alters the recipient's gut microbiota to restore its composition and provide therapeutic benefits. It involves transferring stool from a healthy donor to a recipient to restore a balanced gut microbiota (Borody and Khoruts, 2012). It has shown high efficacy in treating recurrent *Clostridioides difficile* infections, with success rates around 85-90% (Benech *et al.,* 2023; Bland *et al.,* 2024). The history of FMT dates to the 4th century and has gained significant recognition since 2013 (Wang *et al.,* 2019). In November 2022, the U.S. FDA approved Rebyota, a faecal microbiota product, for medical use. Additionally, in April 2023, Vowst, the first orally administered faecal microbiota product, received FDA approval (Do).
- **Engineered Microbial Therapies:** Advancements in genetic engineering have led to the development of probiotics designed to perform specific therapeutic functions. In May 2023, interim results from a first-in-human study revealed that a CRISPR-based microbial gene therapy could eliminate antibiotic-resistant *E. coli* strains in the gut, marking a significant milestone in combating antibiotic resistance (Bai *et al.,* 2023).
- **Microbiome Modulation in Neurodegenerative Diseases:** Emerging research suggests that modulating the gut microbiome may influence the progression of neurodegenerative diseases (Hashim and Makpol, 2022). A clinical trial is underway to evaluate the impact of gut microbiome modulation on slowing or stopping the progression of Parkinson's disease, highlighting the potential of microbiome-targeted therapies in neurodegenerative disorders (Salim *et al.,* 2023; Zhu *et al.,* 2022).

Despite these advancements, challenges remain in the development and application of microbiome-based therapeutics:

- **Safety and Efficacy**: Ensuring the safety and consistent efficacy of microbiome interventions is paramount. The complex and individualized nature of the human microbiome necessitates personalized approaches to treatment.
- **Regulatory Frameworks**: Establishing clear regulatory guidelines is essential to

facilitate the development and approval of microbiome-based therapies.

- **Mechanistic Understanding**: A deeper understanding of the mechanisms by which microbiome alterations influence health and disease will enhance therapeutic design and application.

In summary, microbiome-based therapeutics represent a rapidly evolving area of medicine with the potential to address a wide range of health conditions. Current ongoing research and clinical trials continue to expand our understanding and application of these innovative therapies.

Precision Medicine and Therapeutic Advancements:

The insights gained from the above-mentioned innovations are paving the way for precision medicine approaches tailored to an individual's unique microbiome. Precision medicine is transforming healthcare by tailoring medical interventions to individual patients based on their unique genetic, environmental, and microbiome profiles (Jobin, 2018). The integration of microbiome research into precision medicine has unlocked new possibilities for diagnosing, preventing, and treating diseases more effectively. Therapeutic advancements leveraging the microbiome are particularly promising, offering personalized approaches that align with a patient's distinct microbial composition and functionality. This personalized approach holds the potential to revolutionize healthcare by:

- **Improved diagnostics:** The microbiome can serve as a biomarker for early detection of diseases and risk stratification, enabling personalized preventive measures. Progress in microbiome profiling allows physicians to discern microbial patterns linked to illnesses including colorectal cancer, diabetes, and autoimmune disorders. These insights provide tailored preventative strategies and prompt treatments, markedly enhancing patient outcomes.
- **Targeted therapeutics:** Microbial signatures can guide the development of targeted therapies that selectively modulate specific microbial populations, restoring microbiome balance. These tailored therapies seek to reestablish microbial equilibrium, tackling the underlying causes of dysbiosis-associated disorders. Microbial-based therapies are being investigated for inflammatory bowel disease (IBD) and neurodegenerative illnesses, since precise regulation of the microbiome may reduce symptoms and enhance quality of life.
- **Probiotics and prebiotics:** Probiotics, live beneficial bacteria, and prebiotics, non-digestible fibers that nourish beneficial bacteria, can be used to enhance the beneficial aspects of the microbiome. Probiotics are very effective in addressing gastrointestinal issues and enhancing immunological function. Prebiotics enhance the efficacy of probiotics and foster a healthy microbial ecosystem.
- **Diet and lifestyle interventions:** Personalized dietary guidance and lifestyle adjustments are essential for maintaining a healthy microbiota. By customizing therapies to specific microbial profiles, doctors may avert dysbiosis and its related disorders. Diets rich in fiber and fermented foods have shown the ability to enhance microbial diversity and mitigate inflammation. Lifestyle variables, such as stress management and physical activity affect microbial health and general wellness.

Despite significant progress, challenges remain in fully harnessing the potential of the microbiome for precision medicine. These challenges include:

- **Microbiome complexity:** The vast complexity of the microbiome and its interactions with the host makes it difficult to identify specific causal relationships between microbes and disease states. Comprehending causal links between microorganisms and disease states requires sophisticated techniques and multidimensional data processing.
- **Individual variability:** The microbiome exhibits substantial inter-individual variability, making it challenging to

develop universally applicable microbiome-based interventions.

- **Standardization of methods:** Standardizing microbiome analysis techniques and data interpretation is crucial for generating reproducible and comparable results.
- **Regulatory frameworks:** Establishing clear regulatory frameworks for microbiome-based therapies is essential to ensure their safety and efficacy. Future research directions include Deciphering host-microbiome interactions: Elucidating the molecular mechanisms underlying host-microbiome interactions will provide deeper insights into disease pathogenesis and therapeutic targets.
- **Developing predictive models:** Integrating microbiome data with other clinical and genetic information into predictive models can enhance personalized risk assessment and treatment selection.
- **Translating research into clinical practice:** Facilitating the translation of microbiome research into clinical practice requires continued collaboration between scientists, clinicians, and regulatory bodies. In conclusion, the field of medical microbiology is undergoing a paradigm shift, driven by technological advancements and a growing appreciation for the microbiome's role in human health. Precision medicine approaches, guided by microbiome data, hold immense potential for improving disease prevention, diagnosis, and treatment. As research continues to unravel the complexity of the microbiome, we can anticipate transformative advancements in healthcare.

Real-Time Microbiome Monitoring Techniques:

Real-time microbiome monitoring is a burgeoning domain in microbiome research and healthcare, enabling instantaneous insights into microbial fluctuations and their direct effects on health. This method improves our comprehension of microbial variations in reaction to environmental influences, dietary modifications, illness advancement, and treatment measures via ongoing or regular evaluation of microbiome makeup and activity. As technologies advance and challenges are addressed, real-time monitoring is poised to become a cornerstone of modern healthcare. The following are some real-time monitoring devices:

Wearable Sensors:

Wearable sensors have developed as a potential tool for the real-time monitoring of physiological data, providing continuous, non-invasive insights into human health. Recent improvements have enhanced their ability to detect biomarkers linked to the gut microbiome, yielding useful insights about microbial activity and its effects on general health (Graña Possamai *et al.*, 2020). These non-invasive gadgets are being engineered to provide ongoing insights on gastrointestinal health and metabolic function, including volatile organic compounds (VOCs) generated by gut microorganisms (Walton et al., 2013). Researchers have developed in vivo wireless sensors capable of monitoring gastrointestinal tract redox states by measuring oxidation-reduction potentials (ORP) (Baltsavias *et al.*, 2019). These sensors are powered and interrogated via ultrasonic waves, enabling real-time, quantitative insights into gut microbial activity. In animal models, such implants have successfully measured ORP over extended periods, paving the way for long-term studies of gut redox pathophysiology and potential clinical applications. The amalgamation of flexible electronics with microfluidics has resulted in the creation of wearable biosensors proficient in monitoring perspiration, interstitial fluid, and other biofluids. These sensors can identify metabolites and indicators associated with microbial metabolism, providing indirect evaluations of gut microbiome activity. These technologies have been investigated for applications spanning healthcare monitoring to sports analytics, underscoring their adaptability and potential for extensive use (Ye *et al.*, 2020).

Lab-on-a-Chip Devices:

Lab-on-a-chip (LOC) technologies

have transformed the examination of the human microbiome by offering advanced platforms that simulate the intricate microenvironment of human organs, especially the gastrointestinal tract (Zarrintaj *et al.,* 2022). These microfluidic devices allow for meticulous regulation of physical and chemical parameters, so enabling comprehensive examination of host-microbiome interactions, disease processes, and treatment responses (Gharib *et al.,* 2022). Recent advancements in gut-on-a-chip technology have markedly improved our capacity to simulate the human intestine and its microbial constituents. These devices replicate essential physiological parameters, such as peristaltic motions, fluid dynamics, and the gut's anaerobic environment, facilitating the prolonged co-culture of human intestinal cells and bacteria. These models precisely replicate human biology, connecting conventional laboratory models with clinical investigations (Jeon *et al.,* 2022). Researchers have created gut-on-a-chip using the widely used Caco2 and HT-29 cell lines to create a dynamic human screening platform for a cortisol-sensing, tryptamine-producing synbiotic aimed at enhancing cognitive function. The synbiotic, SYN, was developed from the well-recognized probiotic *E. coli* Nissle 1917 strain. It had the capability to detect cortisol at physiological levels, leading to the activation of a genetic circuit that synthesizes tryptophan decarboxylase and transforms bioavailable tryptophan into tryptamine (Nelson *et al.,* 2022).

Lab-on-a-chip technologies have proved significant in simulating gastrointestinal illnesses and evaluating treatment strategies. Researchers have investigated inflammatory processes associated with illnesses such as inflammatory bowel disease (IBD) by integrating immune cells into gut-on-a-chip devices (Yilmaz et al., 2024). These models enable the examination of immune responses to microbial stimuli and the effectiveness of anti-inflammatory therapies in a regulated environment (Siwczak *et al.,* 2021). Moreover, intestine-on-a-chip models have been used to investigate the effects of certain food constituents on gastrointestinal health. By replicating the gastrointestinal environment and including diverse nutrients, these devices clarify the impact of food on microbial composition and activity, offering insights into dietary strategies for metabolic disorders (Wheeler *et al.,* 2024). The accuracy and versatility of lab-on-a-chip technology make it an essential instrument for customized medicine. Utilizing patient-derived cells, these devices may simulate unique gut environments, facilitating the evaluation of tailored reactions to pharmaceuticals, probiotics, or dietary modifications (Naik and Misra, 2021). This method shows potential for customizing medicines based on individual microbiome profiles, improving therapeutic effectiveness, and reducing side effects. Notwithstanding considerable advancements, obstacles persist in completely emulating the intricacy of the human gastrointestinal tract and its microbiota. The development of models that include numerous microbial populations, several cell types, and the complex architecture of the gut is under progress. Future research seeks to improve the physiological relevance of these models, prolong their lifespan, and include real-time monitoring capabilities to examine dynamic interactions within the gut ecosystem.

Smart Toilets:

Smart toilets are developing as novel instruments for health monitoring, using modern technology to analyze human waste for the early diagnosis of illnesses and ongoing health evaluation. These gadgets provide non-invasive, real-time insights about an individual's health state by incorporating sensors and analytical tools. They are equipped with sensors and analytic capabilities can assess stool samples in real time. Smart toilets are designed to identify various illness indicators in faeces and urine, including those associated with colorectal and urologic malignancies (Tasoglu, 2022). The researchers at Stanford University have created a smart toilet that examines excrement to detect indicators of different health disorders, with the objective of enabling early

diagnosis and enhancing patient outcomes (Park *et al.,* 2020). Furthermore, the smart toilets can assess physiological metrics, like urine flow, which may indicate bladder or prostate problems. Toto's "Flowsky" toilet resembles a conventional toilet but is engineered to identify irregularities in urine flow, aiding in the early diagnosis of any health issues. The gut microbiota is essential for general health, affecting several physiological systems. Smart toilets may aid in preserving a healthy gut microbiome by offering sophisticated, non-invasive techniques for monitoring and evaluating intestinal flora (Grego *et al.,* 2022). These devices provide frequent monitoring, helping the detection of imbalances or alterations in the microbiome, so allowing for prompt treatments to enhance gut health. The smart toilets can effortlessly interact with digital health systems, improving remote monitoring and telemedicine functionalities. By supplying continuous health data, they let healthcare practitioners to monitor patients' situations in real-time, promoting prompt actions and tailored treatment regimens. This integration facilitates the transition to proactive health management and precision medicine.

Ethical Considerations and the Need for Regulatory Frameworks:

The clinical use of microbiome-based therapies introduces critical ethical and regulatory challenges that must be addressed to ensure their safe and equitable implementation (de Leon-Derecho and Dable-Tupas, 2025). Privacy and data security are of paramount importance, as microbiome data can reveal highly sensitive information, including genetic predispositions and health conditions. Safeguarding patient confidentiality and ensuring informed consent for data use are essential components of ethical research and clinical practice (Hoffmann, 2019). Additionally, equitable access to microbiome-based therapies must be prioritized to prevent disparities in healthcare. Advanced interventions, such as faecal microbiota transplantation (FMT) or engineered probiotics, must be made accessible to underserved populations to avoid exacerbating existing inequalities in medical care.

Regulatory frameworks play a pivotal role in translating microbiome research into clinical applications. However, the absence of standardized guidelines for the development, testing, and approval of microbiome-based therapies poses significant challenges (Rodriguez *et al.,* 2024; Waheed *et al.,* 2024). Uniform protocols for manufacturing processes, such as those used for probiotics or FMT products, are essential to prevent contamination and variability that could compromise patient safety. International collaboration is vital for establishing harmonized standards, given the global nature of microbiome research and its implications for public health (Cernava *et al.,* 2022). Furthermore, addressing these challenges requires active engagement among researchers, clinicians, policymakers, and regulatory agencies. Effective collaboration can ensure that emerging therapies are rigorously evaluated for safety and efficacy, while ethical frameworks are established to guide their application. As microbiome-based interventions continue to evolve, a commitment to ethical integrity and robust regulatory oversight will be critical in maximizing their potential to improve health outcomes and minimize risks.

Conclusion and Future Directions:

The human microbiome, a vast and diverse community of microorganisms residing in the human body, plays a critical role in maintaining health and influencing various physiological processes. Disruptions in the microbiome, or dysbiosis, are increasingly linked to a wide range of diseases, including metabolic, neurological, and immunological disorders. Advances in medical microbiology, powered by next-generation sequencing, metagenomics, gnotobiotic animal models, and human microbiome studies, have revolutionized our understanding of these microbial communities. These innovations enable the identification and quantification of microbial

populations, the analysis of their genetic material, and the exploration of causal relationships between specific microbes and host. Precision medicine approaches guided by microbiome data have shown immense potential in transforming healthcare. By leveraging an individual's unique microbial composition, clinicians can tailor preventive measures, develop targeted therapies, and utilize interventions such as probiotics, prebiotics, and dietary modifications to promote a healthy microbiome. These personalized strategies are not only advancing disease prevention and diagnosis but are also redefining treatment paradigms for dysbiosis-associated conditions. Moreover, microbiome-based therapeutics, including faecal microbiota transplantation, engineered probiotics, and microbiome-informed dietary plans, provide promising avenues for addressing chronic diseases and complex disorders like neurodegenerative diseases, autoimmune conditions, and cancer. Despite these achievements, significant challenges remain in fully harnessing the microbiome's potential for precision medicine (Fig. 4). The inherent complexity of the microbiome, coupled with substantial inter-individual variability, complicates the identification of universal therapeutic targets. The absence of standardized methodologies for microbiome analysis and data interpretation limits reproducibility, while ethical and regulatory frameworks must evolve to ensure the safe and equitable implementation of microbiome-based therapies. These barriers underscore the need for interdisciplinary collaboration among researchers, clinicians, and policymakers.



Fig. 4: Factors Influencing Microbiota-Driven Chronic Inflammation.

To address these challenges and maximize the clinical potential of microbiome research, several key actions are recommended:

- **Advance standardization efforts**: Researchers must develop universal protocols for sample collection, sequencing, and data analysis to enhance reproducibility across studies. Creating centralized databases for microbiome research will further facilitate comparative analyses and the development of robust therapeutic strategies.

- **Enhance Multi-Omics Integration**: Combining genomics, transcriptomics, metabolomics, and proteomics data will provide a more holistic understanding of host-microbiome interactions. This integration can identify novel biomarkers and therapeutic targets, improving predictive models for disease risk and treatment responses.
- **Focus on Real-Time Microbiome Monitoring**: Innovations such as wearable biosensors and lab-on-a-chip devices should be prioritized to enable continuous monitoring of microbial dynamics. These tools will help clinicians respond promptly to microbial shifts and optimize personalized treatment strategies.
- **Broaden Population Diversity in Research**: Addressing underrepresentation of various ethnic and demographic groups in microbiome studies is essential for developing globally applicable therapies. Further exploration of age- and gender-specific microbial patterns will also inform tailored interventions.
- **Translate Research into Clinical Practice**: Clinicians should work to integrate microbiome data into routine healthcare, leveraging tools such as electronic health records for precision diagnostics and treatment. Conducting clinical trials to evaluate the long-term efficacy and safety of microbiome-based therapies, including FMT and engineered probiotics, will bridge the gap between research and real-world applications.

Looking ahead, future research must focus on deciphering the intricate host-microbiome interactions and elucidating the molecular mechanisms that underpin these relationships. Integrating microbiome data with other omics technologies and clinical information will refine predictive models for disease risk and therapeutic response, enabling more precise and effective interventions. Real-time microbiome monitoring, facilitated by innovations in wearable biosensors and lab-on-a-chip technologies, holds the promise of transforming our ability to track microbial dynamics and respond promptly to health fluctuations. The field of microbiome research is poised for groundbreaking advancements that will shape the future of healthcare. As we continue to unravel the intricacies of microbial ecosystems and their interactions with the host, we can anticipate transformative improvements in personalized treatment, global health policies, and our foundational understanding of human biology. These strides will not only revolutionize disease management but also address pressing global challenges such as antibiotic resistance, undernutrition, and chronic disease prevention, paving the way for a healthier and more resilient population.

Declarations:

Ethical Approval: Not appicable

Conflict of interests: The author declares no conflicts of interest of any kind.

Authors Contributions: All aspects of this research article, from planning to writing, were conducted solely by the author (Main author).

Funding: The authors declare that no funds, grants, or other support were received during the preparation of this manuscript

Availability of Data and Materials: This study is a review article and does not involve the collection or generation of new data. Any additional information can be obtained from the corresponding author upon request.

Acknowledgements: I would like to express my gratitude to the Laboratory Medicine Department, Al-Baha University, Al-Baha, Saudi Arabia for providing research support.

REFERENCES

Abouelela, M.E., Helmy, Y.A., 2024. Next-generation probiotics as novel therapeutics for improving human health: current trends and future perspectives. *Microorganisms,* 12 (3), 430.

Ahmed, E., Hens, K., 2022. Microbiome in precision psychiatry: An overview of the ethical challenges regarding microbiome big data and microbiome-based interventions. *AJOB Neuroscience,* 13(4), 270-

286.

Aizpurua, O., Dunn, R.R., Hansen, L.H., Gilbert, M.T.P., Alberdi, A., 2024. Field and laboratory guidelines for reliable bioinformatic and statistical analysis of bacterial shotgun metagenomic data. *Critical Reviews in Biotechnology*, 44(6), 1164-1182.

Alsayed, A.R., Abed, A., Khader, H.A., Al-Shdifat, L.M., Hasoun, L., Al-Rshaidat, M.M., Alkhatib, M., Zihlif, M., 2023. Molecular Accounting and Profiling of Human Respiratory Microbial Communities: Toward Precision Medicine by Targeting the Respiratory Microbiome for Disease Diagnosis and Treatment. *International Journal of Molecular Sciences*, 24(4), 4086.

Bai, X., Huang, Z., Duraj-Thatte, A.M., Ebert, M.P., Zhang, F., Burgermeister, E., Liu, X., Scott, B.M., Li, G., Zuo, T., 2023. Engineering the gut microbiome. *Nature Reviews Bioengineering*, 1(9), 665-679.

Baltsavias, S., Van Treuren, W., Weber, M.J., Charthad, J., Baker, S., Sonnenburg, J.L., Arbabian, A., 2019. In vivo wireless sensors for gut microbiome redox monitoring. *IEEE Transactions on Biomedical Engineering*, 67(7), 1821-1830.

Basic, M., Bleich, A., 2019. Gnotobiotics: past, present and future. *Laboratory Animals*, 53(3), 232-243.

Beghini, F., McIver, L.J., Blanco-Míguez, A., Dubois, L., Asnicar, F., Maharjan, S., Mailyan, A., Manghi, P., Scholz, M., Thomas, A.M., 2021. Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. *elife*, 10, e65088.

Benech, N., Barbut, F., Fitzpatrick, F., Krutova, M., Davies, K., Druart, C., Cordaillat-Simmons, M., Heritage, J., Guery, B., Kuijper, E., 2023. Update on microbiota-derived therapies for recurrent Clostridioides difficile infections, 2023. *Clinical Microbiology and Infection*, 30(4), 462-468.

Biagini, F., Calvigioni, M., Lapomarda, A., Vecchione, A., Magliaro, C., De Maria, C., Montemurro, F., Celandroni, F., Mazzantini, D., Mattioli-Belmonte, M., 2020. A novel 3D in vitro model of the human gut microbiota. *Scientific reports*, 10(1), 21499.

Bland, C.M., Love, B.L., Jones, B.M., 2024. Human microbiome: Impact of newly approved treatments on C. difficile infection. *American Journal of Health-System Pharmacy*, zxae 249.

Bober, J.R., Beisel, C.L., Nair, N.U., 2018. Synthetic biology approaches to engineer probiotics and members of the human microbiota for biomedical applications. *Annual Review of Biomedical Engineering*, 20(1), 277-300.

Borody, T.J., Khoruts, A., 2012. Fecal microbiota transplantation and emerging applications. *Nature Reviews Gastroenterology & Hepatology*, 9(2), 88-96.

Brothers, K.B., Rothstein, M.A., 2015. Ethical, legal and social implications of incorporating personalized medicine into healthcare. *Personalized Medicine*, 12(1), 43-51.

Burns, A.R., Guillemin, K., 2017. The scales of the zebrafish: host–microbiota interactions from proteins to populations. *Current Opinion in Microbiology*, 38, 137-141.

Carding, S., Verbeke, K., Vipond, D.T., Corfe, B.M., Owen, L.J., 2015. Dysbiosis of the gut microbiota in disease. *Microbial Ecology in Health and Disease*, 26(1), 26191.

Cernava, T., Rybakova, D., Buscot, F., Clavel, T., McHardy, A.C., Meyer, F., Meyer, F., Overmann, J., Stecher, B., Sessitsch, A., 2022. Metadata

harmonization–Standards are the key for a better usage of omics data for integrative microbiome analysis. *Environmental Microbiome*, 17(1), 33.

Chen, F., Guo, S., Li, Y., Lu, Y., Liu, L., Chen, S., An, J., Zhang, G., 2025. Fusobacterium nucleatum-driven CX3CR1+ PD-L1+ phagocytes route to tumor tissues and reshape tumor microenvironment. *Gut Microbes*, 17(1), 2442037.

Chou, S., Zhang, S., Guo, H., Chang, Y.-f., Zhao, W., Mou, X., 2022. Targeted antimicrobial agents as potential tools for modulating the gut microbiome. *Frontiers in Microbiology*, 13, 879207.

Consortium, H.M.P., 2012. Structure, function and diversity of the healthy human microbiome. *Nature*, 486(7402), 207-214.

Cook, R., Brown, N., Rihtman, B., Michniewski, S., Redgwell, T., Clokie, M., Stekel, D.J., Chen, Y., Scanlan, D.J., Hobman, J.L., 2024. The long and short of it: benchmarking viromics using Illumina, Nanopore and PacBio sequencing technologies. *Microbial Genomics*, 10(2), 001198.

Cowieson, A., 2022. Comparative biology of germ-free and conventional poultry. *Poultry Science*, 101(10), 102105.

Cristofori, F., Dargenio, V.N., Dargenio, C., Miniello, V.L., Barone, M., Francavilla, R., 2021. Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: a door to the body. *Frontiers in Immunology*, 12, 578386.

D'Urso, F., Broccolo, F., 2024. Applications of Artificial Intelligence in Microbiome Analysis and Probiotic Interventions—An Overview and Perspective Based on the Current State of the Art. *Applied Sciences*, 14(19), 8627.

Das, S., Bhattacharjee, M.J., Mukherjee, A.K., Khan, M.R., 2023. Recent advances in understanding of multifaceted changes in the vaginal microenvironment: implications in vaginal health and therapeutics. *Critical Reviews in Microbiology*, 49(2), 256-282.

de Leon-Derecho, C.M.P., Dable-Tupas, G., 2025. Ethical considerations in microbiome research, Human Microbiome Drug Targets. Elsevier, pp. 179-188.

Do, W.Y.C., Two FDA-Approved Fecal Microbiota Products.

Dréno, B., Araviiskaia, E., Berardesca, E., Gontijo, G., Sanchez Viera, M., Xiang, L., Martin, R., Bieber, T., 2016. Microbiome in healthy skin, update for dermatologists. *Journal of the European Academy of Dermatology and Venereology*, 30(12), 2038-2047.

Fong, W., Li, Q., Yu, J., 2020. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. *Oncogene*, 39(26), 4925-4943.

Gharib, G., Bütün, İ., Muganlı, Z., Kozalak, G., Namlı, İ., Sarraf, S.S., Ahmadi, V.E., Toyran, E., Van Wijnen, A.J., Koşar, A., 2022. Biomedical applications of microfluidic devices: a review. *Biosensors*, 12(11), 1023.

Graña Possamai, C., Ravaud, P., Ghosn, L., Tran, V.-T., 2020. Use of wearable biometric monitoring devices to measure outcomes in randomized clinical trials: a methodological systematic review. *BMC Medicine*, 18, 1-11.

Grego, S., Welling, C.M., Miller, G.H., Coggan, P.F., Sellgren, K.L., Hawkins, B.T., Ginsburg, G.S., Ruiz, J.R., Fisher, D.A., Stoner, B.R., 2022. A hands-free stool sampling system for monitoring intestinal health and disease. *Scientific Reports*, 12(1), 10859.

Grenier, T., Leulier, F., 2020. How commensal microbes shape the

physiology of Drosophila melanogaster. *Current Opinion in Insect Science,* 41, 92-99.

Grobeisen-Duque, O., Mora-Vargas, C.D., Aguilera-Arreola, M.G., Helguera-Repetto, A.C., 2023. Cycle biodynamics of women's microbiome in the urinary and reproductive systems. *Journal of Clinical Medicine,* 12(12), 4003.

Hamamah, S., Lobiuc, A., Covasa, M., 2024. Antioxidant Role of Probiotics in Inflammation-Induced Colorectal Cancer. *International Journal of Molecular Sciences,* 25(16), 9026.

Han, Y., He, J., Li, M., Peng, Y., Jiang, H., Zhao, J., Li, Y., Deng, F., 2024. Unlocking the Potential of Metagenomics with the PacBio High-Fidelity Sequencing Technology. *Microorganisms,* 12 (12), 2482.

Hare, P.J., LaGree, T.J., Byrd, B.A., DeMarco, A.M., Mok, W.W., 2021. Single-cell technologies to study phenotypic heterogeneity and bacterial persisters. *Microorganisms,* 9(11), 2277.

Hashim, H.M., Makpol, S., 2022. A review of the preclinical and clinical studies on the role of the gut microbiome in aging and neurodegenerative diseases and its modulation. *Frontiers in Cellular Neuroscience,* 16, 1007166.

Hemmati, M.A., Monemi, M., Asli, S., Mohammadi, S., Foroozanmehr, B., Haghmorad, D., Oksenych, V., Eslami, M., 2024. Using new technologies to analyze gut microbiota and predict cancer risk. *Cells,* 13(23), 1987.

Hoffmann, D.E., 2019. The Promise and Challenges of Microbiome-Based Therapies. *Journal of Law Medicine & Ethics,* 47(4), 476-481.

Hromada, S., Venturelli, O.S., 2023. Gut microbiota interspecies interactions shape the response of Clostridioides difficile to clinically relevant antibiotics. *Plos Biology,* 21(5), e3002100.

Hsu, C.-Y., Khachatryan, L.G., Younis, N.K., Mustafa, M.A., Ahmad, N., Athab, Z.H., Polyanskaya, A.V., Kasanave, E.V., Mirzaei, R., Karampoor, S., 2024. Microbiota-derived short chain fatty acids in pediatric health and diseases: from gut development to neuroprotection. *Frontiers in Microbiology,* 15, 1456793.

Huang, W.-C., Chen, Y.-H., Chuang, H.-L., Chiu, C.-C., Huang, C.-C., 2019. Investigation of the effects of microbiota on exercise physiological adaption, performance, and energy utilization using a gnotobiotic animal model. *Frontiers in Microbiology,* 10, 1906.

Invernizzi, R., Lloyd, C.M., Molyneaux, P.L., 2020. Respiratory microbiome and epithelial interactions shape immunity in the lungs. *Immunology,* 160(2), 171-182.

Jeon, M.S., Choi, Y.Y., Mo, S.J., Ha, J.H., Lee, Y.S., Lee, H.U., Park, S.D., Shim, J.-J., Lee, J.-L., Chung, B.G., 2022. Contributions of the microbiome to intestinal inflammation in a gut-on-a-chip. *Nano Convergence,* 9(1), 8.

Jobin, C., 2018. Precision medicine using microbiota. *Science,* 359(6371), 32-34.

Kennedy, E.A., King, K.Y., Baldridge, M.T., 2018. Mouse microbiota models: comparing germ-free mice and antibiotics treatment as tools for modifying gut bacteria. *Frontiers in Physiology,* 9, 417794.

Kim, C., Pongpanich, M., Porntaveetus, T., 2024. Unraveling metagenomics through long-read sequencing: A comprehensive review. *Journal of Translational Medicine,* 22(1), 111.

Kim, D.-K.C., 2025. Gut Microbiota-Immune System Interactions in Health and Neurodegenerative Diseases: Insights into Molecular Mechanisms and Therapeutic Applications. *Aging*

and Disease, 16(6), 2.

Konstantinov, S.R., Kuipers, E.J., Peppelenbosch, M.P., 2013. Functional genomic analyses of the gut microbiota for CRC screening. *Nature Reviews Gastroenterology & Hepatology*, 10(12), 741-745.

Kubelkova, K., Benuchova, M., Kozakova, H., Sinkora, M., Krocova, Z., Pejchal, J., Macela, A., 2016. Gnotobiotic mouse model's contribution to understanding host–pathogen interactions. *Cellular and Molecular Life Sciences*, 73, 3961-3969.

Kumar, A., Baruah, A., Tomioka, M., Iino, Y., Kalita, M.C., Khan, M., 2020. Caenorhabditis elegans: a model to understand host–microbe interactions. *Cellular and Molecular Life Sciences*, 77, 1229-1249.

Kumar, A., Yadav, A., 2024. Next Generation Sequencing in Metagenomics and Metatranscriptomics, Multi-Omics Analysis of the Human Microbiome: From Technology to Clinical Applications. Springer, pp. 49-75.

Lagkouvardos, I., Intze, E., Schaubeck, M., Rooney, J.P., Hecht, C., Piloquet, H., Clavel, T., 2023. Early life gut microbiota profiles linked to synbiotic formula effects: A randomized clinical trial in European infants. *The American Journal of Clinical Nutrition*, 117(2), 326-339.

Lange, M.E., Clarke, S.T., Boras, V.F., Brown, C.L., Zhang, G., Laing, C.R., Uwiera, R.R., Montina, T., Kalmokoff, M.L., Taboada, E.N., 2023. Commensal Escherichia coli Strains of Bovine Origin Competitively Mitigated *Escherichia coli* O157: H7 in a Gnotobiotic Murine Intestinal Colonization Model with or without Physiological Stress. *Animals*, 13(16), 2577.

Lee, H.-J., Kim, M., 2022. Skin barrier function and the microbiome. *International Journal of Molecular Sciences*, 23(21), 13071.

Lehtoranta, L., Ala-Jaakkola, R., Laitila, A., Maukonen, J., 2022. Healthy vaginal microbiota and influence of probiotics across the female life span. *Frontiers in Microbiology*, 13, 819958.

Li, C., Wang, H., Wen, Y., Yin, R., Zeng, X., Li, K., 2024. GenoM7GNet: An Efficient N 7-Methylguanosine Site Prediction Approach Based on a Nucleotide Language Model. *IEEE/ACM Transactions on Computational Biology and Bioinformatics*, doi: 10.1109/ TCBB.2024.3459870

Li, R., Li, J., Zhou, X., 2024. Lung microbiome: new insights into the pathogenesis of respiratory diseases. *Signal Transduction and Targeted Therapy*, 9(1), 19.

Liu, X., Tan, X., Yu, Y., Niu, J., Zhao, B., Wang, Q., 2025. Short chain fatty acids mediates complement C1q pathway alleviation of perioperative neurocognitive disorders. *Neuropharmacology*, 265, 110266.

Loh, J.S., Mak, W.Q., Tan, L.K.S., Ng, C.X., Chan, H.H., Yeow, S.H., Foo, J.B., Ong, Y.S., How, C.W., Khaw, K.Y., 2024. Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases. *Signal Transduction and Targeted Therapy*, 9(1), 37.

Lozupone, C.A., Knight, R., 2007. Global patterns in bacterial diversity. *Proceedings of the National Academy of Sciences* ,104(27), 11436-11440.

Ma, J., Li, J., Jin, C., Yang, J., Zheng, C., Chen, K., Xie, Y., Yang, Y., Bo, Z., Wang, J., 2023. Association of gut microbiome and primary liver cancer: A two-sample Mendelian randomization and case–control study. *Liver International*, 43(1), 221-233.

Mahmoudian, F., Gheshlagh, S.R., Hemati, M., Farhadi, S., Eslami, M., 2025.

The influence of microbiota on the efficacy and toxicity of immunotherapy in cancer treatment. *Molecular Biology Reports*, 52(1), 86.

Marwaha, K., Cain, R., Asmis, K., Czaplinski, K., Holland, N., Mayer, D.G., Chacon, J., 2025. Exploring the Complex Relationship Between Psychosocial Stress and the Gut Microbiome: Implications for Inflammation and Immune Modulation. *Journal of Applied Physiology*, doi: 10.1152/japplphysiol.00652.2024

Mathuria, A., Chaudhary, A., Sharma, H., Mani, I., 2024. Multi-omics in Gut Microbiome, Multi-Omics Analysis of the Human Microbiome: From Technology to Clinical Applications. Springer, pp. 181-213.

Mazur, M., Tomczak, H., Lodyga, M., Czajkowski, R., Żaba, R., Adamski, Z., 2021. The microbiome of the human skin and its variability in psoriasis and atopic dermatitis. *Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii*, 38(2), 205-209.

Meštrović, T., Matijašić, M., Perić, M., Čipčić Paljetak, H., Barešić, A., Verbanac, D., 2020. The role of gut, vaginal, and urinary microbiome in urinary tract infections: from bench to bedside. *Diagnostics*, 11(1), 7.

Morais, L.H., Schreiber IV, H.L., Mazmanian, S.K., 2021. The gut microbiota–brain axis in behaviour and brain disorders. *Nature Reviews Microbiology*, 19(4), 241-255.

Naik, A., Misra, S.K., 2021. Modern sensing approaches for predicting toxicological responses of food-and drug-based bioactives on microbiomes of gut origin. *Journal of Agricultural and Food Chemistry*, 69(23), 6396-6413.

National Academies of Sciences, E., Medicine, 2018. Animal models for microbiome research: advancing basic and translational science: proceedings of a workshop. Washington (DC): National Academies Press (US).

Nazir, A., Hussain, F.H.N., Raza, A., 2024. Advancing microbiota therapeutics: the role of synthetic biology in engineering microbial communities for precision medicine. *Frontiers in Bioengineering and Biotechnology*, 12, 1511149.

Nelson, M.T., Coia, H.G., Holt, C., Greenwood, E.S., Narayanan, L., Robinson, P.J., Merrill, E.A., Litteral, V., Goodson, M.S., Saldanha, R.J., 2022. Evaluation of human performance aiding live synthetically engineered bacteria in a gut-on-a-chip. *ACS Biomaterials Science & Engineering*, 9(9), 5136-5150.

Nogal, A., Valdes, A.M., Menni, C., 2021. The role of short-chain fatty acids in the interplay between gut microbiota and diet in cardio-metabolic health. *Gut Microbes*, 13(1), 1897212.

Ohara, T.E., Hsiao, E.Y., 2025. Microbiota–neuroepithelial signalling across the gut–brain axis. *Nature Reviews Microbiology*, 1-14.

Park, S.-m., Won, D.D., Lee, B.J., Escobedo, D., Esteva, A., Aalipour, A., Ge, T.J., Kim, J.H., Suh, S., Choi, E.H., 2020. A mountable toilet system for personalized health monitoring via the analysis of excreta. *Nature Biomedical Engineering*, 4(6), 624-635.

Pathak, A., Roy, M., Puno, G., Shankar, G., Mohanty, B., Pandiyarajan, A.P., Baraskar, S.M., Chaudhary, K., 2025. Human microbiome and respiratory diseases, Human Microbiome Drug Targets. Elsevier, pp. 123-131.

Pavlopoulos, G.A., Baltoumas, F.A., Liu, S., Selvitopi, O., Camargo, A.P., Nayfach, S., Azad, A., Roux, S., Call, L., Ivanova, N.N., 2023. Unraveling the functional dark

matter through global metagenomics. *Nature*, 1-9.

Peixoto, R.S., Voolstra, C.R., Sweet, M., Duarte, C.M., Carvalho, S., Villela, H., Lunshof, J.E., Gram, L., Woodhams, D.C., Walter, J., 2022. Harnessing the microbiome to prevent global biodiversity loss. *Nature Microbiology*, 7(11), 1726-1735.

Pereira, R., Oliveira, J., Sousa, M., 2020. Bioinformatics and computational tools for next-generation sequencing analysis in clinical genetics. *Journal of Clinical Medicine*, 9(1), 132.

Poletti, M., Arnauts, K., Ferrante, M., Korcsmaros, T., 2021. Organoid-based models to study the role of host-microbiota interactions in IBD. *Journal of Crohn's and Colitis*, 15(7), 1222-1235.

Profir, M., Enache, R.M., Roşu, O.A., Pavelescu, L.A., Creţoiu, S.M., Gaspar, B.S., 2025. Malnutrition and Its Influence on Gut sIgA–Microbiota Dynamics. *Biomedicines*, 13(1), 179.

Quince, C., Walker, A.W., Simpson, J.T., Loman, N.J., Segata, N., 2017. Shotgun metagenomics, from sampling to analysis. *Nature Biotechnology*, 35(9), 833-844.

Rauth, S., Karmakar, S., Batra, S.K., Ponnusamy, M.P., 2021. Recent advances in organoid development and applications in disease modeling. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 1875(2), 188527.

Reuter, J.A., Spacek, D.V., Snyder, M.P., 2015. High-throughput sequencing technologies. *Molecular Cell*, 58(4), 586-597.

Rodriguez, J., Cordaillat-Simmons, M., Badalato, N., Berger, B., Breton, H., de Lahondès, R., Deschasaux-Tanguy, M., Desvignes, C., D'Humières, C., Kampshoff, S., 2024. Microbiome testing in Europe: navigating analytical, ethical and regulatory challenges. *Microbiome*, 12(1), 258.

Rowland, I., Gibson, G., Heinken, A., Scott, K., Swann, J., Thiele, I., Tuohy, K., 2018. Gut microbiota functions: metabolism of nutrients and other food components. *European Journal of Nutrition*, 57, 1-24.

Russell, M.W., Muste, J.C., Kuo, B.L., Wu, A.K., Singh, R.P., 2023. Clinical trials targeting the gut-microbiome to effect ocular health: a systematic review. *Eye*, 1-9.

Sadeghpour Heravi, F., 2024. Host-vaginal microbiota interaction: shaping the vaginal microenvironment and bacterial vaginosis. *Current Clinical Microbiology Reports*, 1-15.

Salim, S., Ahmad, F., Banu, A., Mohammad, F., 2023. Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment. *Journal of Advanced Research*, 50, 83-105.

Saraf, V.S., Sheikh, S.A., Ahmad, A., Gillevet, P.M., Bokhari, H., Javed, S., 2021. Vaginal microbiome: normalcy vs dysbiosis. *Archives of Microbiology*, 203, 3793-3802.

Satam, H., Joshi, K., Mangrolia, U., Waghoo, S., Zaidi, G., Rawool, S., Thakare, R.P., Banday, S., Mishra, A.K., Das, G., 2023. Next-generation sequencing technology: current trends and advancements. *Biology*, 12(7), 997.

Sedghi, L., DiMassa, V., Harrington, A., Lynch, S.V., Kapila, Y.L., 2021. The oral microbiome: Role of key organisms and complex networks in oral health and disease. *Periodontology*, 2000 87(1), 107-131.

Shang, Z., Pai, L., Patil, S., 2024. Unveiling the dynamics of gut microbial interactions: a review of dietary impact and precision nutrition in gastrointestinal health. *Frontiers in Nutrition*, 11, 1395664.

Sherwin, E., Dinan, T.G., Cryan, J.F., 2018. Recent developments in

understanding the role of the gut microbiota in brain health and disease. *Annals of the New York Academy of Sciences*, 1420(1), 5-25.

Siwczak, F., Loffet, E., Kaminska, M., Koceva, H., Mahe, M.M., Mosig, A.S., 2021. Intestinal stem cell-on-chip to study human host-microbiota interaction. *Frontiers in Immunology*, 12, 798552.

Subramanian, I., Verma, S., Kumar, S., Jere, A., Anamika, K., 2020. Multi-omics data integration, interpretation, and its application. *Bioinformatics and Biology Insights*, 14, 1177932219899051.

Tang, W.W., Kitai, T., Hazen, S.L., 2017. Gut microbiota in cardiovascular health and disease. *Circulation Research*, 120(7), 1183-1196.

Tang, W.W., Li, D.Y., Hazen, S.L., 2019. Dietary metabolism, the gut microbiome, and heart failure. *Nature Reviews Cardiology*, 16(3), 137-154.

Tasoglu, S., 2022. Toilet-based continuous health monitoring using urine. *Nature Reviews Urology*, 19(4), 219-230.

Tiwari, A., Ika Krisnawati, D., Susilowati, E., Mutalik, C., Kuo, T.-R., 2024. Next-Generation Probiotics and Chronic Diseases: A Review of Current Research and Future Directions. *Journal of Agricultural and Food Chemistry*, 72(50), 27679-27700.

Tkach, S., Dorofeyev, A., Kuzenko, I., Boyko, N., Falalyeyeva, T., Kobyliak, N., 2023. Fecal Microbiota Transplantation in Diseases Not Associated with Clostridium difficile: Current Status and Future Therapeutic Option, Microbiome in 3P Medicine Strategies: The First Exploitation Guide. Springer, pp. 275-308.

Tlaskalová-Hogenová, H., Štěpánková, R., Kozáková, H., Hudcovic, T., Vannucci, L., Tučková, L., Rossmann, P., Hrnčíř, T., Kverka, M., Zákostelská, Z., 2011. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. *Cellular & Nolecular Immunology*, 8(2), 110-120.

Trisal, A., Singh, I., Garg, G., Jorwal, K., Singh, A.K., 2025. Gut–brain axis and brain health: modulating neuroinflammation, cognitive decline, and neurodegeneration. *3 Biotech*, 15(1), 25.

Turnbaugh, P.J., Ley, R.E., Hamady, M., Fraser-Liggett, C.M., Knight, R., Gordon, J.I., 2007. The human microbiome project. *Nature*, 449(7164), 804-810.

Van den Abbeele, P., Deyaert, S., Thabuis, C., Perreau, C., Bajic, D., Wintergerst, E., Joossens, M., Firrman, J., Walsh, D., Baudot, A., 2023. Bridging preclinical and clinical gut microbiota research using the ex vivo SIFR® technology. *Frontiers in Microbiology*, 14, 1131662.

Van Hul, M., Neyrinck, A.M., Everard, A., Abot, A., Bindels, L.B., Delzenne, N.M., Knauf, C., Cani, P.D., 2024. Role of the intestinal microbiota in contributing to weight disorders and associated comorbidities. *Clinical Microbiology Reviews*, 37(3), e00045-00023.

Venema, K., Van den Abbeele, P., 2013. Experimental models of the gut microbiome. *Best Practice & Research Clinical Gastroenterology*, 27(1), 115-126.

Visekruna, A., Luu, M., 2021. The role of short-chain fatty acids and bile acids in intestinal and liver function, inflammation, and carcinogenesis. *Frontiers in Cell and Developmental Biology*, 9, 703218.

Vitorino, R., 2024. Transforming Clinical Research: The Power of High-

Throughput Omics Integration. *Proteomes*, 12(3), 25.

Vlasova, A.N., Rajashekara, G., Saif, L.J., 2018. Interactions between human microbiome, diet, enteric viruses and immune system: novel insights from gnotobiotic pig research. *Drug Discovery Today: Disease Models*, 28, 95-103.

Waheed, R., Farooq, A.Z., Asma, L., 2024. Regulatory Considerations for Microbiome-Based Therapeutics, Human Microbiome: Techniques, Strategies, and Therapeutic Potential. Springer, pp. 657-689.

Walton, C., Fowler, D.P., Turner, C., Jia, W., Whitehead, R.N., Griffiths, L., Dawson, C., Waring, R.H., Ramsden, D.B., Cole, J.A., 2013. Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases. *Inflammatory Bowel Diseases*, 19(10), 2069-2078.

Wan, X., Yang, Q., Wang, X., Bai, Y., Liu, Z., 2023. Isolation and Cultivation of Human Gut Microorganisms: A Review. *Microorganisms*, 11(4), 1080.

Wang, B., Yao, M., Lv, L., Ling, Z., Li, L., 2017. The human microbiota in health and disease. *Engineering*, 3(1), 71-82.

Wang, J.-W., Kuo, C.-H., Kuo, F.-C., Wang, Y.-K., Hsu, W.-H., Yu, F.-J., Hu, H.-M., Hsu, P.-I., Wang, J.-Y., Wu, D.-C., 2019. Fecal microbiota transplantation: Review and update. *Journal of the Formosan Medical Association*, 118, S23-S31.

Westfall, S., Lomis, N., Kahouli, I., Dia, S.Y., Singh, S.P., Prakash, S., 2017. Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis. *Cellular and Molecular Life Sciences*, 74, 3769-3787.

Wheeler, A.E., Stoeger, V., Owens, R.M., 2024. Lab-on-chip technologies for exploring the gut–immune axis in metabolic disease. *Lab on a Chip*, 24, 1266-1292.

Wostmann, B.S., 2020. Germfree and gnotobiotic animal models: background and applications. CRC Press, London.

Wu, X., Yang, X., Dai, Y., Zhao, Z., Zhu, J., Guo, H., Yang, R., 2024. Single-cell sequencing to multi-omics: technologies and applications. *Biomarker Research*, 12(1), 110.

Xia, Y., Li, X., Wu, Z., Nie, C., Cheng, Z., Sun, Y., Liu, L., Zhang, T., 2023. Strategies and tools in illumina and nanopore-integrated metagenomic analysis of microbiome data. *iMeta*, 2(1), e72.

Xu, J., Yang, Y., 2020. Implications of gut microbiome on coronary artery disease. *Cardiovascular Diagnosis and Therapy*, 10(4), 869.

Ye, S., Feng, S., Huang, L., Bian, S., 2020. Recent progress in wearable biosensors: From healthcare monitoring to sports analytics. *Biosensors*, 10(12), 205.

Yilmaz, E.G., Hacıosmanoğlu, N., Jordi, S.B.U., Yilmaz, B., Inci, F., 2024. Revolutionizing IBD research with on-chip models of disease modeling and drug screening. *Trends in Biotechnology*, https://doi.org/10.1016/j.tibtech.2024.10.002

Yoo, J.Y., Groer, M., Dutra, S.V.O., Sarkar, A., McSkimming, D.I., 2020. Gut microbiota and immune system interactions. *Microorganisms*, 8(10), 1587.

Zarrintaj, P., Saeb, M.R., Stadler, F.J., Yazdi, M.K., Nezhad, M.N., Mohebbi, S., Seidi, F., Ganjali, M.R., Mozafari, M., 2022. Human Organs-on-Chips: A Review of the State-of-the-Art, Current Prospects, and Future Challenges. *Advanced Biology*, 6(1), 2000526.

Zeng, H., Umar, S., Rust, B., Lazarova, D., Bordonaro, M., 2019. Secondary bile acids and short chain fatty acids in

the colon: a focus on colonic microbiome, cell proliferation, inflammation, and cancer. *International Journal of Molecular Sciences,* 20(5), 1214.

Zhang, X., Liang, Z., Wang, S., Lu, S., Song, Y., Cheng, Y., Ying, J., Liu, W., Hou, Y., Li, Y., 2019. Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical Oncology. *Cancer Biology & Medicine,* 16(1), 189.

Zhao, M., Zhou, L., Wang, S., 2025. Immune crosstalk between respiratory and intestinal mucosal tissues in respiratory infections. *Mucosal Immunology,* https://doi.org/10.1016/j.mucimm.2024.12.013

Zhu, M., Liu, X., Ye, Y., Yan, X., Cheng, Y., Zhao, L., Chen, F., Ling, Z., 2022. Gut microbiota: a novel therapeutic target for Parkinson's disease. *Frontiers in Immunology,* 13, 937555.